Tags

Type your tag names separated by a space and hit enter

Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Eur J Pharmacol. 2020 Oct 05; 884:173455.EJ

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic potentials of strategies directed towards SARS-CoV2-ACE2 binding, the renin-angiotensin system, and the kinin-kallikrein system. SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, ACE2 blockers, soluble ACE2, and host protease inhibitors. In conclusion, blocking or manipulating the SARS-CoV2-ACE2 binding interface perhaps offers the best tactic against the virus that should be treated as a fundamental subject of future research.

Authors+Show Affiliations

Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Student Research Committee, Babol University of Medical Sciences, Babol, Iran.Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Student Research Committee, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Student Research Committee, Babol University of Medical Sciences, Babol, Iran.Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: rezaei_nima@tums.ac.ir.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32745604

Citation

Sharifkashani, Sourena, et al. "Angiotensin-converting Enzyme 2 (ACE2) Receptor and SARS-CoV-2: Potential Therapeutic Targeting." European Journal of Pharmacology, vol. 884, 2020, p. 173455.
Sharifkashani S, Bafrani MA, Khaboushan AS, et al. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting. Eur J Pharmacol. 2020;884:173455.
Sharifkashani, S., Bafrani, M. A., Khaboushan, A. S., Pirzadeh, M., Kheirandish, A., Yavarpour Bali, H., Hessami, A., Saghazadeh, A., & Rezaei, N. (2020). Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting. European Journal of Pharmacology, 884, 173455. https://doi.org/10.1016/j.ejphar.2020.173455
Sharifkashani S, et al. Angiotensin-converting Enzyme 2 (ACE2) Receptor and SARS-CoV-2: Potential Therapeutic Targeting. Eur J Pharmacol. 2020 Oct 5;884:173455. PubMed PMID: 32745604.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting. AU - Sharifkashani,Sourena, AU - Bafrani,Melika Arab, AU - Khaboushan,Alireza Soltani, AU - Pirzadeh,Marzieh, AU - Kheirandish,Ali, AU - Yavarpour Bali,Hanie, AU - Hessami,Amirhossein, AU - Saghazadeh,Amene, AU - Rezaei,Nima, Y1 - 2020/07/31/ PY - 2020/05/27/received PY - 2020/07/30/revised PY - 2020/07/30/accepted PY - 2020/8/4/pubmed PY - 2020/9/23/medline PY - 2020/8/4/entrez KW - ACE2 KW - COVID-19 KW - Origin KW - SARS-CoV2 KW - Therapeutic KW - Transmission SP - 173455 EP - 173455 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 884 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic potentials of strategies directed towards SARS-CoV2-ACE2 binding, the renin-angiotensin system, and the kinin-kallikrein system. SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, ACE2 blockers, soluble ACE2, and host protease inhibitors. In conclusion, blocking or manipulating the SARS-CoV2-ACE2 binding interface perhaps offers the best tactic against the virus that should be treated as a fundamental subject of future research. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/32745604/Angiotensin_converting_enzyme_2__ACE2__receptor_and_SARS_CoV_2:_Potential_therapeutic_targeting_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(20)30547-1 DB - PRIME DP - Unbound Medicine ER -